Medical technology company HeartBeam Inc (NASDAQ:BEAT) on Tuesday announced a strategic collaboration with the Icahn School of Medicine at Mount Sinai in New York to accelerate the development and validation of next-generation AI-ECG algorithms.

The partnership combines HeartBeam's 3D ECG signal collection platform with Mount Sinai's artificial intelligence and clinical expertise to expand access to clinical-grade heart monitoring in home settings.

HeartBeam's platform captures the heart's electrical activity from three non-coplanar dimensions and is capable of collecting synthesised 12-lead ECG data from patients anytime and anywhere over time. The collaboration aims to generate longitudinal, high-fidelity datasets from home-based monitoring, enabling the development of increasingly personalised AI algorithms for wellness and clinical applications, including heart attack risk assessment.

By integrating HeartBeam's growing dataset with Mount Sinai's clinically annotated ECG data, the initiative is expected to accelerate AI model training and validation. The partnership is designed to support the development of patient-focused insights, disease assessments, and chronic condition management tools, positioning HeartBeam to expand beyond symptom-based rhythm monitoring into AI-driven cardiac disease assessment and management.